<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The complementarity determining region 3 (CDR3) of the immunoglobulin (Ig) heavy chain variable region (VH) is the most reliable molecular fingerprint for most if not <z:hpo ids='HP_0000001'>all</z:hpo> human B cells </plain></SENT>
<SENT sid="1" pm="."><plain>The nucleotide sequence encoding for any B-cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific VH CDR3 is currently identified by PCR sequencing based on procedures involving the usage of either radioactive materials, patient/family-specific primers, or <z:mp ids='MP_0001794'>bacterial</z:mp> cloning </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: In six consecutive patients with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> we assessed the feasibility of a method that allows for identification of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific VH CDR3 using consensus primers while avoiding both radioactive materials and <z:mp ids='MP_0001794'>bacterial</z:mp> cloning procedures </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific VH CDR3 was successfully identified in <z:hpo ids='HP_0000001'>all</z:hpo> six patients in nearly half the time typically required by any other method currently utilized </plain></SENT>
<SENT sid="4" pm="."><plain>The feasibility of the proposed method was not significantly affected either by the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific Ig isotype, or by the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> infiltration in the original biopsy specimen </plain></SENT>
<SENT sid="5" pm="."><plain>In the three patients for whom <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> specimen-derived hybridomas were available, the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific VH CDR3 was also found in at least 8 of 10 of them </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: The proposed method allows the ability to quickly identify the B-cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific VH CDR3 using consensus primers while avoiding radioactive materials and <z:mp ids='MP_0001794'>bacterial</z:mp> cloning procedures </plain></SENT>
</text></document>